Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation.
Liver recipients who have antibodies to hepatitis B core antigen (anti-HBc) or received an anti-HBc positive liver graft are at risk of acquiring de novo hepatitis B infection so a life long prophylaxis is required. A post-transplant vaccination against hepatitis B virus (HBV) can offer a better alternative than either hepatitis B hyperimmune globulin (HBIG) or lamivudine. This study investigated the course of anti-HBs titer after vaccination and analyzed the factors that influence the response. Between October 1999 and February 2003, 37 pediatric patients were given a post-transplant vaccination when an anti-HBc positive graft was used, the recipient was anti-HBc positive, or when anti-HBs titer was below 20 IU/L irrespective of the serological status. Thirty-three patients responded to the vaccine and did not require further HBIG injections at a mean follow up of 33.6 months. Fifteen patients were good responder and only needed a single set of vaccines, and 18 were poor responder needing additional boosters. Two patients developed de novo hepatitis B infection and two required additional HBIG injections. Preoperative severity of liver disease, serological status of HBV of recipient or donor, use of HBIG or pulse steroid therapy, type of vaccines, and dose or time interval between doses had no influence on response rate. Recipients with a high preoperative anti-HB titer, small graft-recipient weight ratio (GRWR), greater catch up growth, heavier body weight, lower tacrolimus level at the time of vaccination, and longer time interval between transplant or steroid medication and vaccination yielded good response. If well tailored, post-transplant vaccination can be effective and offer patients prophylaxis against de novo hepatitis B infection for a prolonged period of time.
Kwon
Choon Hyuck David
CH
Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
Suh
Kyung-Suk
KS
Yi
Nam-Joon
NJ
Chang
Seong-Hwan
SH
Cho
Yong Beom
YB
Cho
Jai-Young
JY
Lee
Hoan Jong
HJ
Seo
Jeong Kee
JK
Lee
Kuhn Uk
KU
D002102:Cadaver; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000097:blood / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006512:Hepatitis B Core Antigens / Q000032:analysis; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006801:Humans; D007117:Immunization, Secondary / Q000706:statistics & numerical data; D007136:Immunoglobulins / Q000627:therapeutic use; D007223:Infant; D016031:Liver Transplantation; D019520:Living Donors / Q000706:statistics & numerical data; D008297:Male; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014611:Vaccination
D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D017325:Hepatitis B Vaccines; D007136:Immunoglobulins; D011994:Recombinant Proteins; C045213:hepatitis B hyperimmune globulin